Study Group: Users of BRACAnalysis Testing for Breast and Ovarian Cancer (US)(?)
Council Members in this Study Group: 49
Request a survey with this Study Group
Leading Experts in this Study Group
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi
Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...
Taral Patel, MDOncologist
Mid Ohio Oncology Hematology Inc.
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...
Professor, Department Chair
Stanford University School of Medicine
Jonathan Berek, MD, MMS, is a Professor and Department Chair of Obstetrics and Gynecology at Stanford University School of Medicine, California. He is the Chief of Obstetrics and Gynecology at Stanford University Hospital and Clinics. Dr. Berek is also the Group Chair of Cooperative Ovarian Cancer...
Robert Gallo, MDOwner
Robert Gallo, MD, Pc
Robert Gallo, MD, is a board-certified Obstetrician-Gynecologist in private practice in Northern New Jersey. He has been in practice for over 24 years and serves a varied group of both obstetric and gynecologic patients. Dr. Gallo is an active laparoscopic and laser surgeon, and his fields of expertise...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
New data with low and high dose of Avastin with Taxoter
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...
CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation
The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Genetic Counselor
- Owner
- Physician - Division Head
- Physician - Department Chair
- Director